कीमोथेरेपी: ओपन एक्सेस
खुला एक्सेस

अमूर्त

Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer

Maria Lucibello and Filippo De Braud

The development of resistance to chemotherapeutics is still a severe event in cancer patients. One of the major obstacles to the effectiveness of cancer therapies is the development of side effects and resistance to therapy. The characterization of novel biomarkers that support a more aggressive phenotype may provide new diagnostic tools and new opportunities for cancer therapy. In the context of breast cancer disease, the phosphorylated form of Translationally controlled tumor protein (phospho-TCTP) appears a new prognostic factor for aggressive breast cancer and tumor progression. Dihydroartemisinin (DHA) is a novel approach to molecular targeted therapies, or combination regimens in advance breast cancer.